Sign Up for Email Alerts
Kineta Inc.
Kineta Inc.
Kineta Inc.
Close
  • About Us
    • company
    • team
    • board
    • SAB
  • pipeline
    • overview
    • KVA12123 (VISTA)
    • CD27
  • partnerships
  • investors
    • overview
    • press releases
    • events & presentations
    • stock information
    • analyst coverage
    • SEC filings
    • corporate governance
    • IRS Form 8937
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean
  • About Us
    • company
    • team
    • board
    • SAB
  • pipeline
    • overview
    • KVA12123 (VISTA)
    • CD27
  • partnerships
  • investors
    • overview
    • press releases
    • events & presentations
    • stock information
    • analyst coverage
    • SEC filings
    • corporate governance
    • IRS Form 8937
  • careers
  • contact
  • en_USEnglish
    • ko_KRKorean

[be_recent_posts_author_no_link title=”Latest News from Kineta” category_id=”4,3″ num_posts=”6″ post_offset=”0″ num_words_limit=”0″ show_date_author=”1″ show_more_link=”0″ more_link_text=”Read more” show_thumbs=”0″ remove_thumb_frame=”0″ thumb_frame_shadow=”0″ default_thumb=”0″ post_thumb_width=”100″ post_thumb_height=”80″]

Recent Kineta News

  • Interim results of the ongoing phase 1/2 clinical trial of KVA12123, an engineered IgG1 targeting VISTA, alone and in combination with pembrolizumab in advanced solid tumors
  • Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
  • Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
  • KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported
  • VISTA a potential new Immuno-oncology therapeutic target to treat human Acute Myeloid Leukemia
Post placeholder image
April 16, 2018 in Biotech Industry News

Kineta inks $360 million-plus deal with Genentech for chronic pain drug

Kineta Inc 3 Like Post Comments Off on Kineta inks $360 million-plus deal with Genentech for chronic pain drug
Read More
Post placeholder image
April 16, 2018 in Biotech Industry News

Roche partners with Kineta to develop non-opioid pain therapy

Kineta Inc 3 Like Post Comments Off on Roche partners with Kineta to develop non-opioid pain therapy
Read More
Post placeholder image
April 16, 2018 in Biotech Industry News

Genentech, Kineta to Partner on Non-Opioid Pain Treatments

Kineta Inc 3 Like Post Comments Off on Genentech, Kineta to Partner on Non-Opioid Pain Treatments
Read More
Post placeholder image
April 16, 2018 in Biotech Industry News

NAChR average pain drug, Kineta bid bags Genentech deal for as much as $359M+

Kineta Inc 3 Like Post Comments Off on NAChR average pain drug, Kineta bid bags Genentech deal for as much as $359M+
Read More
Post placeholder image
April 16, 2018 in Biotech Industry News

Kineta, Roche’s Genentech strike chronic pain deal

Kineta Inc 3 Like Post Comments Off on Kineta, Roche’s Genentech strike chronic pain deal
Read More
Post placeholder image
April 16, 2018 in Biotech Industry News

Kineta inks $360 million-plus deal with Genentech for chronic pain drug

Kineta Inc 3 Like Post Comments Off on Kineta inks $360 million-plus deal with Genentech for chronic pain drug
Read More
Post placeholder image
March 12, 2018 in Biotech Industry News

Non-addictive Cone Snail Therapy Could Help with Chronic Pain, Crains

Kineta Inc 0 Like Post Comments Off on Non-addictive Cone Snail Therapy Could Help with Chronic Pain, Crains
Read More
Post placeholder image
September 25, 2017 in Biotech Industry News

Seattle biotech company developing non-opioid painkiller, King 5 News

Kineta Inc 0 Like Post Comments Off on Seattle biotech company developing non-opioid painkiller, King 5 News
Read More
Post placeholder image
September 6, 2017 in Biotech Industry News

Inside Perspectives: Will Immunotherapy Knock Out Cancer?

Kineta Inc 0 Like Post Comments Off on Inside Perspectives: Will Immunotherapy Knock Out Cancer?
Read More
Post placeholder image
September 2, 2017 in Biotech Industry News

Inside Perspectives on Cancer Immunotherapy: An Interview with Kineta’s Shawn Iadonato

Kineta Inc 0 Like Post Comments Off on Inside Perspectives on Cancer Immunotherapy: An Interview with Kineta’s Shawn Iadonato
Read More
Prev123456Next

219 Terry Ave. N. Suite 300. Seattle, WA 98109

Sign Up for Email Alerts

219 Terry Ave. N. Suite 300. Seattle, WA 98109

  • About Us
  • pipeline
  • partnerships
  • investors
  • contact
Sign Up for Email Alerts

© 2024 Kineta Inc. Privacy Policy Terms of Use

English
English
Korean